Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...

Shares of Moderna (NASDAQ:MRNA) traded ~7% higher in the premarket on Thursday after the company swung back to profits on better-than-expected revenue in Q3 thanks to its updated COVID-19 vaccine. The ...

The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same ...

Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.

Summer's rise in COVID-19 cases led to the approval of updated versions of vaccinations targeting recent strains for the 2024 ...

The options include the mRNA vaccines from Pfizer/BioNTech and Moderna — the vaccines that the vast majority ... Please ...